Fig. 2: Vaccine immunogenicity and targetability of driver mutations.
From: A neoantigen vaccine generates antitumour immunity in renal cell carcinoma
a, Peripheral T cell immune responses following vaccination, measured using IFNγ ELISpot assays. Left, heatmap showing the dynamics of ex vivo T cell responses for each patient and each peptide pool. m.v. denotes missing values. White numbers in the heatmap indicate the absolute magnitude of the maximum per patient response, in spot-forming units per 106 PBMCs. Right, the number of immunogenic individual peptides in each pool following in vitro stimulation. b, Summary of flow cytometry immunophenotyping and intracellular cytokine staining for all patients with assessable responses in the study cohort. c, Example IFNγ ELISpot images against an RCC driver mutation (VHL) from patient 101 PBMCs at week 16 following in vitro stimulation with a vaccine peptide pool, with dimethylsulfoxide (DMSO) and HIV peptides as negative controls, and phytohaemagglutinin (PHA) as a positive control, in triplicate. VHLmut, mutant VHL peptide. d, Per patient immunogenicity of the five common RCC driver mutations in this study. e, Immunogenicity of pan-cancer driver and passenger mutations. f, Heatmap showing the median normalized levels of circulating plasma proteins before and after vaccination. Normalized protein expression for each soluble factor (z score).
